Skip to main content

Market access for medical technologies in Lithuania

A brief overview of key market access pathways and challenges for medical devices, in-vitro diagnostic tests in Lithuania


Key topics

There is only one key theme describing market access for medical technologies in Lithuania: 

  • Reimbursement: payment mechanism via the DRG system, add-on reimbursement


Hospital care is reimbursed via the DRG system. 

DRGs are determined by the combination of a procedure code (List of surgical and medical procedures, an adjustment of the Australian ACHI classification) and a diagnosis code (ICD-10-AM). The procedure coding list and the DRG system are maintained by the Lithuanian Health Insurance Fund, but the possibilities for establishing new codes and DRGs are limited, as the entire system is adopted from Australia (AR-DRG system; in theory, every four years). DRG cost weights are updated annually.In addition, certain high cost devices (mostly implants) are reimbursed in addition to the DRG tariff.

The payment system is maintained by the Lithuanian Health Insurance Fund.


Specifics for IVD tests

In-vitro diagnostic tests provided in ambulatory settings are reimbursed on a fee-for-service basis via the List of specialist consultations, maintained by the Lithuanian Health Insurance Fund.

How can MTRC help?

Development of reimbursement analysis (procedure coding, payment mechanism, reimbursement tariffs, policy and HTA considerations)

Development of reimbursement strategy 

Get in touch

Contact us to discuss your needs and learn about our services